NCT04704258已完成不适用
Clinical Study of a Novel Transcatheter Anti-embolic Filter (FLOWer) for Cerebral Protection During Aortic Valve Interventions
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 16
- 主要终点
- Reduction in total volume of new cerebral lesions in all territories at serial DWMRI
研究概览
简要总结
The purpose of this clinical study is to assess the safety, performance, and treatment effect of the use of the AorticLab FLOWer System, in preventing cerebral thromboembolic complications in patients with indication for a TAVI (Transcatheter Aortic Valve Implant).
详细描述
A single arm, prospective, multicenter non-randomized clinical study of the AorticLab FLOWer System to prevent embolic complications during transcatheter aortic valve procedures.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects of age ≥ 18 years
- •Subject is scheduled to undergo transfemoral aortic valve implant (TAVI) procedure on a stenotic native aortic valve and is qualified based on pre-operative CT-scan examination (trans-thoracic echocardiogram (TTE) can be used as confirmatory assessment)
- •Subject anatomy with Ilio-femoral artery segment compatible with a 12 F device catheter size
- •The subject and the treating physician agree that the subject will undergo the scheduled pre-procedural testing and return for all required post-procedure follow-up visits
- •The subject, or legally authorized representative, has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved by the appropriate Medical Ethics Committee (EC) or Institutional Review Board (IRB)
排除标准
- •Clinical exclusion criteria (preoperative screening)
- •Subjects with hypercoagulable state that cannot be corrected by additional periprocedural heparin
- •Subjects with contraindication to cerebral MRI
- •Subjects with a history of a stroke or transient ischemic attack within the prior 6 months
- •Subjects with known diagnosis of acute myocardial infarction (AMI) within 30 days preceding the index procedure
- •Renal insufficiency (creatinine > 3.0 mg/dL or Glomerular Filtration Rate GFR < 30) and/or renal replacement therapy at the time of screening
- •Subjects with a history of bleeding diathesis or coagulopathy or patients in whom anti-platelet and/or anticoagulant therapy is contraindicated, patients who will refuse transfusion, or patients with an active peptic ulcer or history of upper gastrointestinal (GI) bleeding within the prior 3 months
- •Subjects with known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, clopidogrel/ticlopidine, nitinol, stainless steel alloy, and/or contrast sensitivity that cannot be adequately pre-medicated
- •Subject is currently participating in another drug or device clinical study or has other medical illnesses that may cause the subject to be non-compliant with the protocol or confound the data interpretation
- •Subjects with a previously implanted prosthetic aortic valve (i.e., planned valve-in-valve with a TAVI)
- •Subject requires an emergent procedure
- •Subject has active major psychiatric disease
- •Subjects with neurodegenerative or other progressive neurological disease or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities
- •Subject has an ejection fraction of 30% or less
- •Subjects with active endocarditis or other systemic infection
- •Subjects undergoing therapeutic thrombolysis
- •Subject is pregnant or lactating. Pregnancy confirmed by positive urine or serum test
- •Computerized Tomographic exclusion criteria (preoperative screening)
- •Subjects with documented friable or mobile atherosclerotic plaque in the aortic arch
- •Subjects with echocardiographic evidence of aortic mass, thrombus or vegetation
- •Subjects with a diameter of the ascending aorta < 25 and > 39 mm at baseline CT (measured 10 mm upstream of the first vessel of the brachiocephalic trunk)
- •Subjects undergoing transcatheter aortic valve implantation (TAVI) via the trans-axillary, trans-subclavian, or trans-aortic route
- •Subjects with severe peripheral arterial, abdominal aortic, or thoracic aortic disease that precludes delivery of sheath vascular access
- •Subjects in whom the aortic arch is heavily calcified, severely atheromatous, or severely tortuous
结局指标
主要结局
Reduction in total volume of new cerebral lesions in all territories at serial DWMRI
时间窗: Within 2-5 days after procedure vs. baseline
Primary Clinical Benefit Endpoint: Reduction in total volume of new cerebral lesions in all territories at serial DWMRI, compared to historical data in control arm (unprotected) data from previous randomized studies
FLOWer Device Safety: Rate of Major Adverse Cardiac and Cerebrovascular Events
时间窗: 30 days
Primary Safety Endpoint: FLOWer device Safety, rate of Major Adverse Cardiac and Cerebrovascular Events (MACCEs) related to FLOWer device and procedure as adjudicated by a Clinical Event Committee. MACCEs are based on the Valve Academic Research Consortium (VARC- 3) criteria: * all death; * all stroke (disabling and non-disabling); * acute kidney injury (stage 3 at discharge or 72 hours post index procedure, whichever occurs first)
次要结局
- Cumulative occurrence of Serious Clinical Events related to FLOWer device and procedure as adjudicated by a Clinical Event Committee.(7 and 30 days)
- Brain imaging (DW-MRI)(Within 2-5 days after procedure vs. baseline)
- Technical Success(Immediately after procedure)
- Debris capture(Immediately after procedure)
- Neurocognitive(2-7 days and 30-days vs. baseline)
- FLOWer System Usability(Immediately after procedure)
研究者
研究点 (16)
Loading locations...
相似试验
已完成
不适用
Neovascularization Embolisation for Knee Osteoarthritis.(NEO)Osteoarthritis, KneeNCT03884049Erasmus Medical Center58
Unknown
不适用
Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas (TACE-KMG)Carcinoma, HepatocellularNCT01393197Tianjin Medical University Cancer Institute and Hospital2,480
Unknown
不适用
Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular CarinomasCarcinoma, HepatocellularNCT01393093Tianjin Medical University Cancer Institute and Hospital2,840
Unknown
不适用
Anti-angiogenic Targeted Drugs Plus Rg3 to Improve the Efficacy of TACE for Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaNCT04523467Eastern Hepatobiliary Surgery Hospital320
已完成
不适用
A Pilot Study Evaluating the Safety and Effectiveness of a New Pleural Catheter for the Medical Management of Symptomatic, Recurrent, Malignant Pleural EffusionsMalignant Pleural EffusionsNCT02227732C. R. Bard10